Who owns Travere Therapeutics, Inc. (RTRX)? Elite investor 13F holders

5 tracked elite investors reported holding Travere Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw, Polen Capital Management, Gotham Asset Management, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-13 00:00:00104137218.00 USD1833079.000000SharesreduceOriginal filing
D.E. ShawTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:0081833044.00 USD1440469.000000SharesaddOriginal filing
D.E. ShawTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000PrincipalexitedOriginal filing
D.E. ShawTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:007644566.00 USD6500000.000000PrincipalbuyOriginal filing
Polen Capital ManagementTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-04 00:00:001949435.00 USD34315.000000SharesbuyOriginal filing
Gotham Asset ManagementTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:001569547.00 USD27628.000000SharesreduceOriginal filing
Tudor InvestmentTRAVERE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:00338304.00 USD5955.000000SharesreduceOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown